Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Anti-oxidants have great potential as treatment for neuropathic pain

Neuropathic pain - pain that results from a malfunction in the nervous system - is a daily reality for millions of Americans. Unlike normal pain, it doesn't go away after the stimulus that provoked it ends, and it also behaves in a variety of other unusual and disturbing ways. Someone suffering from neuropathic pain might experience intense discomfort from a light touch, for example, or feel as though he or she were freezing in response to a slight change in temperature.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.

30 Jul 2013

Study finds that higher-frequency electric current stimulation of the spinal cord reduces pain faster

An animal study in the August issue of Anesthesiology suggests that higher-frequency electric current stimulation of the spinal cord reduced pain quicker and better reached nerves not affected by traditionally used frequencies. A higher frequency and intensity controlled pain faster and more effectively, the study found.

25 Jul 2013

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease.

12 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Olfactory ensheathing cells treatment improves neurological function in SCI patients: Study

A team of researchers in Poland who treated three of six paraplegics with spinal cord injury using transplanted olfactory ensheathing cells found that the three treated patients showed neurological improvement and no adverse effects while the three control patients who did not receive transplants saw no improvement.

29 Jun 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Study explores analgesic activity of ceftriaxone in humans

A single dose of the antibiotic ceftriaxone given for antimicrobial prophylaxis prior to surgery enhanced patient pain thresholds after the procedure, according to a study published in The Journal of Pain, the peer review publication of the American Pain Society.

26 Jun 2013

Zalicus advancing Z944 into further clinical development

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013.

4 Jun 2013

Emory University researchers identify a protein that stimulates orphan receptors in the brain

Researchers at Emory University have identified a protein that stimulates a pair of "orphan receptors" found in the brain, solving a long-standing biological puzzle and possibly leading to future treatments for neurological diseases.

22 May 2013

UTMB researchers awarded grant to study gene therapy techniques to eliminate neuropathic pain

University of Texas Medical Branch at Galveston researchers have been awarded a five-year, $1.8 million grant by the National Institute of Neurological Disorders and Stroke to apply the techniques of gene therapy to the problem of neuropathic pain - that is, pain that arises from a malfunction in the nervous system.

21 May 2013

Insero Health announces top-line Phase Ib trial results of INS001 in patients with drug-resistant epilepsy

Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.

17 May 2013

NINDS Director affirms NIH's committed to support pain research at APS meeting

In her keynote address to the 32nd American Pain Society Annual Scientific Conference, Story Landis, PhD, director of the National Institute for Neurological Disorders and Stroke, told the APS audience that NIH is committed to research to improve understanding of the biological basis of pain and the development of effective treatments.

10 May 2013

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1 in 10 stroke patients suffer chronic and debilitating pain, typically described as sharp, stabbing or burning. It's called central poststroke pain syndrome (CPSP). It was first described more than 100 years ago, and it is treatable with medications and magnetic or electrical stimulation of the brain.

9 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

5 May 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Chronic daily pain continues to be burden for limb-injured veterans, says pain management expert

Veterans who sustained major limb injuries during combat reported little improvement in symptoms of depression, anxiety, post-traumatic stress disorder and other mental-health problems up to 2 years post injury, according to research presented today.

15 Apr 2013